| Work Detail |
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (Helix or the Company), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announces the appointment of Dr. Theordore J. Witek, Jr. to the board of directors of Helix. Dr. Witek brings over three decades of clinical development, medical affairs and commercial experience to Helix''s board. Dr. Witek currently holds the position of Senior Vice President, Corporate Partnerships and Chief Scientific Officer of Innoviva Inc. Dr. Witek is also a Professor & Senior Fellow at the Institute of Health Policy, Management & Evaluation at the Dalla Lana School of Public Health, University of Toronto. Previously, Dr. Witek served as President and Chief Executive Officer, Boehringer Ingelheim Canada Ltd. Joining Boehringer in 1992, Dr. Witek held a number of positions of increasing responsibility. In 2001, he moved to Germany to lead the operating team for Spiriva® where he also served as the Boehringer Ingelheim Co-chair of the Joint Operating Committee with Pfizer in their global alliance. During his tenure in Canada, Dr. Witek served on the Board of Directors at Innovative Medicines Canada (formerly Rx&D), Canada''s National Association for Research-Based Pharmaceutical Companies, chairing its Health Technology Assessment Committee and Public Affairs Committee. He also served over ten years on the Drug/Device Discovery and Development Committee of the American Thoracic Society, serving as Chairman from 2010 to 2012. Dr. Witek holds a Doctor of Public Health degree from Columbia University, a Master of Public Health from Yale University, and a Master of Business Administration from Henley Management College. Ted''s robust clinical, regulatory and medical affairs experience will add tremendous depth to Helix''s board of directors, said Dr. Sven Rohmann, Chief Executive Officer of Helix. |
